|
|
|
| Preliminary evaluation of the performance and clinical application of a domestic quantitative RT-PCR assay for Detection of HIV-1 nucleic acid |
| TAN Jie1,3, DENG Zhongping2,3,4, ZHENG Fang5, DING Feng3, LIU Rangjiao6, TIAN Xiangrong1 |
1. School of Biology and Environmental Science, Jishou University, Jishou 416000, China;
2. Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China;
3. Hunan Provincial Key Laboratory of Genetic Diagnosis Technology, Changsha 410205, China;
4. Hunan Normal University, Changsha 410081, China;
5. The First Hospital of Changsha, Changsha 410005, China;
6. SANWAY Clinical Laboratories INC, Changsha 410205, China |
|
|
|
|
Abstract Objective To preliminarily evaluate the detection performance and clinical applicability of a newly developed Real-Time Quantitative PCR Kit for HIV-1 RNA detection (referred to as Sansure HIV-1). Methods The genotype detection ability, limit of detection, specificity and quantitative detection accuracy of the Sansure HIV-1 were investigated by using WHO HIV-1 serum, National Standards of HIV-1 RNA and clinical samples positive for blood-borne infection pathogens collected by SANWAY Clinical Laboratories INC as samples. The remaining 374 of clinical samples tested by Roche Cobas TaqMan HIV-1 Version 2.0 (referred to as Cobas HIV-1) were collected to evaluate the clinical diagnosis performance of Sansure HIV-1. Statistical methods such as correlation and Bland-Altman analysis were used to compare the performance of the two assays. Results (1) The 10 cases of WHO Subtype Blood inventory detected by Sansure HIV-1 were all positive. (2) The absolute deviation between the logarithmic value of each sample concentration and the theoretical logarithmic value did not exceed ±0.4 log orders of magnitude. (3) The positive rates were 100% when the HIV-1 RNA National Standards were diluted to 50 IU/mL and 25 IU/mL, and the positive rate was 75% when diluted to 12.5 IU/mL. All clinically similar pathogen were tested negative using Sansure HIV-1, and no cross-reaction occurred. (4) The positive rates of Cobas HIV-1 and Sansure HIV-1 in testing 374 clinical samples were both 66.84% (250/374) . (5) Taking the Cobas HIV-1 test results as a reference, the positive consistency of the Sansure HIV-1 reached 99.20% (95%CI: 96.82%-99.86%) , and the negative consistency was 98.38% (95%CI: 93.71%-99.72%) , and the total consistency was 98.93% (95%CI: 94.04%-99.75%) . (6) The linear regression equation of 248 samples tested positive by both assays was y=0.8357x+0.7379, and the r was 0.8901 (P<0.0001) . (7) Further, Bland-Altman analysis showed the SD was 0.5606 (Log10 IU/ mL) , confirmed that the RT-PCR quantitative results detected by the two reagents were highly consistent. Conclusion The evaluated Sansure HIV-1 assay has good quantitative accuracy and good subtype detection coverage for HIV group M, Group O and group N with a detection sensitivity of 25 IU/mL. There is no cross-reaction with common clinical blood-borne pathogens. Sansure HIV-1 showed great consistency in terms of positive detection rate and quantitative results compared with Roche Cobas HIV-1 in testing clinical plasma samples, Considering cost-effectiveness and accessibility, the Sansure HIV-1 assay kit has good clinical applicability and can suitable for the requirements of most clinical applications.
|
|
Received: 09 January 2024
|
|
|
|
|
|
[1] 周全华, 王越, 刘华, 等. 某国产人类免疫缺陷病毒1型核酸定量检测试剂的临床试验研究[J]. 检验医学与临床, 2021, 18(5) : 585-588.
[2] 陈灿, 周彩虹. 某医学院大学生艾滋病知识与防艾生活技能现状及影响因素研究[J]. 湖南师范大学学报 (医学版) , 2023, 20(01) : 114-118.
[3] UNAIDS. Fact sheet-Latest global and regional statistics on the status of the AIDS epidemic[R]. Accessed: July 2023.
[4] Political Declaration on HIV and AIDS: Ending Inequalities and Getting on Track to End AIDS by2030[EB/OL]. (2021-06-09) . https: //undocs. org/A/RES/75/284.
[5] 严亚军, 桂希恩, 冯玲, 等. 261例新发现的HIV感染者病毒载量分析[J]. 中国艾滋病性病, 2019, 25(10) : 1019-1021.
[6] LESOSKY M, RABOUD IM, GLASS T, et al.Comparison of guidelines for HIV viral load monitoringamong pregnant and breastfeeding women in sub-Saharan Africal[J]. AIDS, 2020, 34(2) : 311-315.
[7] ESTILL I, EGGER M, BLASER N, et al.Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study[J]. AIDS, 2013, 27(9) : 1483-1492.
[8] CARMONA S, PETER T, BERRIE L.HIV viral load scale-up: multipleinterventions to meet the HIV treatment cascade[J]. Curr Opin HIV AIDS, 2017, 12(2) : 157-164.
[9] PETER T, ELLENBERGER D, KIM AA, et al.Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring[J]. Lancet Infect Dis, 2017, 17(1) : e26-e29.
[10] 中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南 (2021年版)[J]. 中国艾滋病性病, 2021, 27(11) : 1182-1201.
[11] 艾滋病防治条例 (2019修订版)[J]. 中国艾滋病性病, 2019, 25(04): 435-438.
[12] SOLLIS KA, SMIT PW, FISCUS S, et al.Systematic review of the performance of HIV viral load technologies on plasma samples[J]. PLoS ONE, 2014, 9(2) : e85869.
[13] 李玉文. 两种HIV抗体初筛试剂盒阳性率的比较分析[J]. 世界临床医学, 2016, 10(15) : 7.
[14] 陈志忠, 李结敏, 廖扬勋, 等. 某国产NAT试剂盒应用于血液筛查的评价与应用[J]. 分子诊断与治疗杂志, 2016, 8(3) : 192-195.
[15] 王述莲, 戴立忠, 陈曦, 等. 两种人类免疫缺陷病毒定量检测试剂的评价研究[J]. 中华医院感染学杂志, 2014, 24(22) : 5461-5464.
[16] HERMANS LE, MOORHOUSE M, CARMONA S, et al.Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment out-comes in WHO-guided South African treatment programmes: amulticentre cohort study[J]. Lancet Infect Dis, 2018, 18(2) : 188-197.
[17] RYSCAVAGE P, KELLY S, LI JZ, et al.Significance and clinical management of persistent low-level viremia and very-low-level viremiain HIV-l-infected patients[J]. Antimicrob Agents Chemother, 2014, 58(7): 3585-3598.
[18] 何林, 万伟, 朱祈钰, 等. 某国产HIV-1病毒载量检测试剂的检测性能评估[J]. 中国艾滋病性病, 2020, 26 (06) : 569-572+586.
[19] 荆凡辉, 吕玮, 李太生. HIV感染者免疫功能重建新视角: CD4/CD8比值[J]. 中国艾滋病性病, 2018, 24(6) : 643-646.
[20] 丁莉莎, 陈曦, 熊晓燕, 等. 一种新型国产试剂检测HIV-1病毒载量[J]. 实用预防医学, 2014, 21(01) : 19-21.
[21] 张岭, 蒋岩, 潘品良. HIV-1病毒载量检测常用技术及研究进展[J]. 传染病信息, 2015, 28(6) : 352-356.
[22] 赵全壁, 赵志超, 宋畅, 等. 一种国产HIV核酸定量试剂与进口试剂的对比研究[J]. 中国艾滋病性病, 2017, 23(7) : 592-595.
[23] 蒋强, 程林, 蔡侃儒, 等. 一种国产HIV-1核酸定量试剂与罗氏试剂的临床对比研究[J]. 热带医学杂志, 2019, 19(4) : 451-454.
[24] NIGHTINGALE S, GERETTI AM, BELOUKAS A, et al.Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia[J]. J Neurovirol, 2016, 22(6) : 852-860.
[25] HELOU E, SHENOI S, KYRIAKIDES T, et al.Characterizing Patientswith Very-Low-Level HIV Viremia: A Community-Based Study[J]. J Int Assoc Provid AIDS Care, 2017, 16(3) : 261-266.
[26] 蔡侃儒, 程林, 陈伟梅, 等. 两种HIV-1RNA定量检测方法的临床对比研究[J]. 中国艾滋病性病, 2019, 25(1) : 18-21.
[27] 杨勇, 蒲伟, 罗小虎. 国产全自动HIV-1核酸定量检测试剂盒的性能评价[J]. 检验医学, 2020, 35(2) : 153-155.
[28] 李繁, 蒋岩, 屈然, 等. 两种HIV-1核酸定量检测试剂盒V2.0的对比研究[J]. 中国艾滋病性病, 2014, 20(3) : 146-153.
[29] WILL G, KIRSTEN W, JAVIER S, et al.Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical Trials[J]. Clin Infect Dis, 2016, 62(7) : 929-934. |
|
|
|
2024, Vol. 21 
